Switching from protease inhibitor-based-HAART to a protease inhibitor-sparing regimen is associated with improved specific HIV-immune responses in HIV-infected children

Simone Pensieroso, Maria Luisa Romiti, Paolo Palma, Guido Castelli-Gattinara, Stefania Bernardi, Elio Freda, Paolo Rossi, Caterina Cancrini

Research output: Contribution to journalArticlepeer-review

Abstract

To evaluate the effects of switching from successful long-term protease inhibitor (PI)-based HAART to a three nucleoside reverse transcriptase inhibitor PI-sparing regimen, viral load quantification, HIV-specific lymphoproliferative assay and T-cell receptor (TCR) spectratyping were performed during 96 weeks of simplification follow-up in 19 HIV-infected children. Our data showed that simplification of therapeutic strategies acts positively on immune competence in HIV paediatric patients. Our children maintained viral suppression, increased lymphoproliferative responses and normalized TCRBV repertoire on the CD8 subset.

Original languageEnglish
Pages (from-to)1893-1896
Number of pages4
JournalAIDS (London, England)
Volume20
Issue number14
DOIs
Publication statusPublished - Sep 2006

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Switching from protease inhibitor-based-HAART to a protease inhibitor-sparing regimen is associated with improved specific HIV-immune responses in HIV-infected children'. Together they form a unique fingerprint.

Cite this